PinnyPeptide

HEP-1 (Gepon) vs VIP (Vasoactive Intestinal Peptide)

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

HEP-1 (Gepon)

Immune

Russian-approved 14-amino-acid immunomodulator derived from the ezrin protein.

Peptide B

VIP (Vasoactive Intestinal Peptide)

Healing & Recovery

Broad neuropeptide with anti-inflammatory, immunomodulatory, and vasodilatory activity.

Typical vial

5 mg

Typical dose

1,000-10,000 mcg

Half-life

Variable per route

FDA status

Not FDA approved. Approved in Russia as Gepon.

Typical vial

5 mg

Typical dose

50-200 (intranasal) mcg

Half-life

~2 minutes (plasma); longer functional duration via tissue distribution

FDA status

Not FDA approved as therapeutic. VIP analog aviptadil receiv…

HEP-1 (Gepon) effects

  • Macrophage activation and cytokine modulation
  • Enhanced mucosal immune defense
  • Antiviral activity in HIV, herpes, hepatitis (Russian clinical use)
  • Anti-inflammatory effects in chronic infectious conditions
  • Restoration of immune function in immunocompromised patients

VIP (Vasoactive Intestinal Peptide) effects

  • Vasodilation and smooth-muscle relaxation
  • Broad anti-inflammatory effects via VPAC1/VPAC2
  • Immunomodulatory: shifts T-helper balance toward Th2/regulatory
  • Circadian rhythm organization (suprachiasmatic nucleus activity)
  • Lung-protective effects in ARDS and pulmonary hypertension models
  • Used clinically in CIRS / biotoxin-illness recovery protocols

HEP-1 (Gepon) side effects

  • Generally well-tolerated in Russian clinical use
  • Mild local irritation with topical or intranasal use
  • Occasional headache
  • Rare allergic reactions
  • Long-term safety with chronic use not extensively studied outside Russia

VIP (Vasoactive Intestinal Peptide) side effects

  • Hypotension and flushing (especially with rapid IV)
  • Tachycardia
  • Headache
  • GI effects (cramping, diarrhea at high doses)
  • Intranasal: occasional nasal irritation

HEP-1 (Gepon) dosing ranges

HIV/AIDS adjunct (Russian clinical)

10 mg · Once daily, oral or rectal · Per clinical protocol

Recurrent herpes (Russian clinical)

2 mg · Topical 3-4 times daily · 7-14 days per outbreak

Mucosal immunity research

1-5 mg · Intranasal or oral · Per research protocol

VIP (Vasoactive Intestinal Peptide) dosing ranges

Intranasal CIRS protocol (off-label)

50 mcg · 4 sprays daily · Per Shoemaker protocol; months to years for full restoration

Research / immunomodulation

Variable per protocol · Per protocol · Per protocol

Full HEP-1 (Gepon) guide → Full VIP (Vasoactive Intestinal Peptide) guide →

HEP-1 (Gepon) vs VIP (Vasoactive Intestinal Peptide) — common questions

What is the difference between HEP-1 (Gepon) and VIP (Vasoactive Intestinal Peptide)?

HEP-1 (Gepon): Russian-approved 14-amino-acid immunomodulator derived from the ezrin protein. Typical dose 1,000-10,000 mcg. VIP (Vasoactive Intestinal Peptide): Broad neuropeptide with anti-inflammatory, immunomodulatory, and vasodilatory activity. Typical dose 50-200 (intranasal) mcg. Both fall under the Immune and Healing & Recovery categories.

Can you stack HEP-1 (Gepon) and VIP (Vasoactive Intestinal Peptide)?

Stacking HEP-1 (Gepon) with VIP (Vasoactive Intestinal Peptide) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, HEP-1 (Gepon) or VIP (Vasoactive Intestinal Peptide)?

HEP-1 (Gepon) is typically dosed: Once daily, oral or rectal for HIV/AIDS adjunct (Russian clinical); Topical 3-4 times daily for Recurrent herpes (Russian clinical); Intranasal or oral for Mucosal immunity research. VIP (Vasoactive Intestinal Peptide) is typically dosed: 4 sprays daily for Intranasal CIRS protocol (off-label); Per protocol for Research / immunomodulation.

Are HEP-1 (Gepon) and VIP (Vasoactive Intestinal Peptide) FDA approved?

HEP-1 (Gepon): Not FDA approved. Approved in Russia as Gepon. VIP (Vasoactive Intestinal Peptide): Not FDA approved as therapeutic. VIP analog aviptadil received Emergency Use Authorization consideration for COVID-19 ARDS but not full approval.

Related peptide comparisons

hep-1 vs thymalinhep-1 vs thymosin-alpha-1hep-1 vs vilonara-290 vs vipbpc-157 vs vipkpv vs vip

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free